Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cassia tora seed ethanolic extract (CSEE) is a botanical preparation derived from the seeds of the *Cassia tora* (also known as *Senna tora*) plant, commonly referred to as sicklepod. Prepared typically using a 70% ethanol solvent, CSEE is being investigated for its potential therapeutic benefits in metabolic disorders such as type 2 diabetes mellitus and insulin resistance. The extract's mechanism of action involves the enhancement of mitochondrial metabolism within the pancreas, which helps to compensate for impaired glucose consumption and improves insulin sensitivity in target tissues. Preclinical research in high-fat diet-fed animal models suggests that CSEE can alleviate basal hyperinsulinemia and improve overall glucose homeostasis by restoring pancreatic mitochondrial function.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cassia tora seed ethanolic extract.